INmune Bio opened at $1.10, in line with its previous close of $1.10. In the last trading session, the stock traded between $1.01 and $1.10. It showed a downward intraday trend.
An investment of $100 made 5 years ago in INmune Bio is now worth
$ 7.18
Resulting in a loss of
$ 92.82 (92.82%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.05 (-4.64%)
Day High
$1.10
Day Low
$1.01
Day Open
$1.10
Prev Close
$1.10
Volume
3,85,961
1W Return
-20.83%
1M Return
-41.13%
3M Return
-49.93%
6M Return
-22.30%
1Y Return
-30.53%
Market Cap ($ Mn)
32
PE Ratio
-
PB Ratio
3.18
PEG Ratio
-
ROE
-164.59%
ROCE
-162.60%
EPS (TTM)
$-0.17
1 Week
-20.83%
1 Month
-41.13%
3 Months
-49.93%
6 Months
-22.30%
9 Months
-33.18%
INmune Bio Q3FY26 Results: Net loss narrows to $4.7 million
Net loss narrowed to $4.7 million in Q3 2026 from $6.5 million in Q3 2025. R&D expenses decreased to $3.2 million from $4.9 million year-over-year. Cash position stands at $16.3 million, supplemented by $4.5 million raised in October. Final pre-MAA package submitted to UK MHRA, targeting complete submission in early 2027.
7 days agoINmune Bio submits pre-MAA for Ebstrocel to UK MHRA
INmune Bio submitted final pre-MAA package for Ebstrocel to UK MHRA. Full MAA submission planned for early February 2027. Potential UK approval anticipated in mid-2027, accelerating timeline by six weeks. Parallel FDA Type B meeting request prepared for Q2 2027 BLA submission.
22 days agoINmune Bio submits EMA regulatory packages for Ebstrocel
INmune Bio submitted EMA packages for Ebstrocel in RDEB. Filings include Orphan Drug Designation and Scientific Advice. Supports planned EU MAA in Q1 2027. UK MAA targeted for Q4 2026; US BLA for Q1 2027.
2mo agoINmune Bio Q2 Results: $4.6M R&D rebates extend cash runway
INmune Bio Inc. secured approximately $4.6 million in R&D rebates from Australia and the UK in mid-2026. The non-dilutive funds exceeded second-quarter operating cash usage, extending the cash runway for its late-stage platforms CORDStrom and XPro1595 as they approach key regulatory filings.
3mo agoINmune Bio completes commercial manufacturing milestone for CORDStrom platform
INmune Bio Inc. has achieved a significant manufacturing milestone by processing its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Stevenage, UK. This advancement supports the planned Phase 3 confirmation clinical trial for Ebstrocel and future regulatory submissions in the US, EU, and UK. The development ensures the company is positioned to generate its first US tested master cell banks for commercial supply.
3mo agoINmune Bio publishes study linking XPro to reduced Alzheimer's risk after TBI
INmune Bio Inc. published a Department of Defense–funded study in the Journal of Neurotrauma demonstrating that its candidate XPro1595 prevented the rise in amyloid pathology and cognitive deficits following traumatic brain injury in mice. The research identifies soluble TNF as a critical link between brain injury and Alzheimer’s disease, showing that neutralizing it mitigates inflammatory cascades.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in INmune Bio is now worth
$ 7.18
Resulting in a loss of
$ 92.82 (92.82%)
Note: Past profits do not guarantee future returns.
